successes, we have the opportunity to aggressively advance
our drugs in development, with significant data milestones planned for our
two most advanced drugs, mipomersen and ISIS 113715, and expand our
pipeline with two to four new drugs. Our partnering successes over the last
year have created substantial interest in Isis and our technology, which we
plan to exploit with new strategic relationships. In short, we believe 2007
is just the beginning of value creation from Isis' antisense platform and
look forward to an exciting upcoming year," concluded Ms. Parshall.
Drug Development Highlights
Isis' cardiovascular franchise matured appreciably during the last
year, with mipomersen at the forefront. The clinical success of mipomersen
has added significant value to the entire drug development pipeline.
* Mipomersen (formerly ISIS 301012) continues to demonstrate an
excellent safety and efficacy profile supported by strong Phase 2
clinical results in all patient populations tested. As a result, Isis
has initiated registration studies of mipomersen in Familial
* Isis established a strategic alliance with BMS for the discovery and
development of antisense drugs targeting PCSK9, an important regulator
of the LDL-receptor.
* Isis initiated IND-enabling studies of ISIS 353512, an antisense drug
that targets C-reactive protein, in partnership with the Korea
Institute of Technology. Isis' metabolic disease franchise continued to expand with the addition
of new diabetes drugs into development, and new research efforts toward
attractive targets for the treatment of obesity.
* Isis continued Phase 2 studies of ISIS 113715 for the treatment of
type 2 diabetes in patients on stable sulfonylurea treatment. In
humans and preclinical studies, ISIS 113715 demonstrated reductions in
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Related medicine news :1
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites2
. Haemacure Reports Third Quarter 2007 Results3
. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion4
. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best5
. MDS Reports Third Quarter 2007 Results6
. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 20067
. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System8
. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results9
. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance10
. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion11
. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.